Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR110894 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAR110894 - 0.5 mg | EXPERIMENTAL | SAR110894, 0.5 mg once daily along with Donepezil. |
| SAR110894 - 2 mg | EXPERIMENTAL | SAR110894, 2 mg once daily along with Donepezil. |
| SAR110894 - 5 mg | EXPERIMENTAL | SAR110894, 5 mg once daily along with Donepezil. |
| Placebo | PLACEBO_COMPARATOR | Placebo (for SAR110894) once daily along with Donepezil. |
| Name | Type | Description |
|---|---|---|
| SAR110894 | DRUG | Pharmaceutical form: Capsule Route of administration: Oral |
| placebo (for SAR110894) | DRUG | Pharmaceutical form: Capsule Route of administration: Oral |
| Donepezil | DRUG | 5 mg or 10 mg once daily continued as taken before inclusion |
Inclusion criteria: * Patients with diagnosis of Alzheimer's Disease (AD) (Cannot be dementia from strokes or other causes). * Patient is on stable and well-tolerated donepezil treatment at a dose of either 5 or 10 mg daily for at least 3 months prior to screening visit. Exclusion criteria: * Age...
SAR110894 is an investigational small molecule being developed for the treatment of dementia of the Alzheimer's type. It is being studied in patients with mild to moderate Alzheimer's disease who are already taking donepezil. The drug is currently in Phase 2 clinical development.
SAR110894 is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is a small molecule in the neurology therapeutic area, targeting dementia of the Alzheimer's type.
SAR110894 is in Phase 2 clinical development. It has completed one Phase 2 trial, and no active trials are currently listed. The drug remains investigational and has not been approved for commercial use.
SAR110894 has been studied in one completed Phase 2 clinical trial with the identifier NCT01266525. This trial evaluated the effect of different doses of SAR110894 on cognition in patients with mild to moderate Alzheimer's disease who were on donepezil. The trial enrolled 291 participants across multiple countries.
Yes, the completed Phase 2 trial of SAR110894 was a randomized, double-blind, placebo-controlled study. It enrolled 291 patients aged 55 years and older with mild to moderate Alzheimer's disease. The trial was conducted in the United States, Australia, Canada, France, Germany, Italy, Poland, Portugal, and Spain.